2020 Annual Meeting | C241 - Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist

Date Thursday 04/30/20

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Logan D. Schneider, MD

Topic(s) Sleep

Learning Objectives Participants should identify limitations of and developments in the diagnostic and therapeutic options for primary CNS hypersomnias. Participants should be able to recognize clinical and diagnostic hallmarks of various parasomnias (from RBD to NREM parasomnias to nocturnal seizures). Participants should be comfortable with understanding when to order and how to interpret state-of-the-field diagnostics in order to diagnose and manage insomnia.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Intermediate

Program Tracks Advanced Practice Provider

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
03:30 PM - 03:35 PM	Introduction	Right Under Your Nose: How to Tell When You're Staring a Sleep Disorder Right in the Face Logan D. Schneider, MD
03:35 PM - 04:10 PM	Speaker	Not as Uncommon as You Might Think: What to Do if a Hypersomnia Patient Ends Up in Your Clinic Emmanuel Mignot, MD, PhD
04:10 PM - 04:45 PM	Speaker	Things That Go Bump in the Night: Exploring Parasomnias and Nocturnal Epilepsy Michael J. Howell, MD, FAAN
04:45 PM - 05:20 PM	Speaker	Not Your Momma’s Insomnia: State-of-the-art Assessment and Breakthroughs in Treatment of Insomnia Charlene Gamaldo, MD, FAAN
05:20 PM - 05:30 PM	Q&A	Questions and Answers

Faculty Disclosures
Logan D. Schneider, MD	Dr. Schneider has received personal compensation for serving as an employee of Alphabet, Inc. Dr. Schneider has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals. Dr. Schneider has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Avadel Pharmaceuticals. Dr. Schneider has received intellectual property interests from a discovery or technology relating to health care.
Michael J. Howell, MD, FAAN	Dr. Howell has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for GEM Health. Dr. Howell has stock in Sleep Performance Institute. The institution of Dr. Howell has received research support from National Institutes of Health. Dr. Howell has received publishing royalties from a publication relating to health care.
Charlene Gamaldo, MD, FAAN	Dr. Gamaldo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for johns hopkins. Dr. Gamaldo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Idorsia. The institution of Dr. Gamaldo has received research support from NIH/NIMH/NIDA/NINDS. Dr. Gamaldo has received publishing royalties from a publication relating to health care.
Emmanuel Mignot, MD, PhD	Dr. Mignot has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Mignot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceutical. Dr. Mignot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals, Inc. . Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for EcoR1. Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for ApneaCo. Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Mignot has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Centessa .

��ɫ��

��ɫ��